TG Therapeutics (TGTX)

TG Therapeutics Stock Analysis & Ratings

TGTX Stock Chart & Stats

Day’s Range$5.75 - $6.25
52-Week Range$5.51 - $41.00
Previous Close$6.1
Average Volume (3M)2.67M
Market Cap$872.39M
P/E Ratio-2.3
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-2.63



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $5.51 and its highest was $41.00 in the past 12 months.
    What is TG Therapeutics’s market cap?
    TG Therapeutics’s market cap is $872.39M.
      What is TG Therapeutics’s price target?
      The average price target for TG Therapeutics is $15.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $23.00 ,the lowest forecast is $5.00. The average price target represents 152.48% Increase from the current price of $6.04.
        What do analysts say about TG Therapeutics?
        TG Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
          When is TG Therapeutics’s upcoming earnings report date?
          TG Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 83 days.
            How were TG Therapeutics’s earnings last quarter?
            Currently, no data Available
            Is TG Therapeutics overvalued?
            According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
              Does TG Therapeutics pay dividends?
              TG Therapeutics does not currently pay dividends.
              What is TG Therapeutics’s EPS estimate?
              TG Therapeutics’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does TG Therapeutics have?
              TG Therapeutics has 144,440,000 shares outstanding.
                What happened to TG Therapeutics’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of TG Therapeutics?
                Among the largest hedge funds holding TG Therapeutics’s share is Maverick Capital ltd. It holds TG Therapeutics’s shares valued at 64M.


                  TG Therapeutics Stock Analysis

                  The TG Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  TG Therapeutics

                  TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

                  Similar Stocks
                  Price & Change
                  Johnson & Johnson
                  Gilead Sciences
                  Calithera Bio

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis